Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's third consecutive day of losses.
CTMX stock touches 52-week low at $0.76 amid market challenges
CytomX Therapeutics Inc . (NASDAQ:CTMX) stock has reached a new 52-week low, trading at $0.76, as the biopharmaceutical company faces a challenging market environment. Despite the recent decline, ...
InsideNoVa5h
Colgan High School senior named finalist in prestigious science and math competition
A Colgan High School senior was named one of the top 40 finalists in the 2025 Regeneron Science Talent Search, a prestigious ...
Managed Healthcare Executive6h
FDA Sets Review Date for Linvoseltamab for Multiple Myeloma
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
The Manila Times10h
Cytokinetics Names Robert E. Landry to Board of Directors
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Leerink Partnrs Has Positive Forecast for REGN Q1 Earnings
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...